Skip to main content
. 2018 Sep 4;9(69):33064–33076. doi: 10.18632/oncotarget.25869

Figure 2. mTORC1/2 inhibition by INK128 is unaffected by carboplatin treatment.

Figure 2

A., B. Samples consisting of equal protein amounts from total cell lysates were resolved by SDS-PAGE and detected by immunoblot. Cells were treated with carboplatin and INK128 as described in the legend to Figure 1. Immunoblots are shown at 24 h post-treatment. Representative blots of 3 independent studies. C. Cells were labeled during indicated drug treatments with 25 µCi of [35S]-methionine-cysteine/mL and specific activity of labeled protein incorporation into nascent protein determined by TCA precipitation. The mean of 3 studies was normalized to controls, with standard error of the mean (SEM) shown. Statistical analysis by paired Student t-test. *, P < 0.01.